With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with a transaction set to propel the company into the CDMO market.

Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer support for drug development customers. The acquisition of Pii enhances ...

Jabil (JBL) announced the acquisition of Pharmaceutics International, completed February 3. “Jabil is very pleased to announce this acquisition. With our shared commitment to creating the best ...

Meanwhile, Jabil’s market share has declined slightly from 5.3% in 2027 to 4.9% in 2024. We noted that Jabil’s revenue in 2024 has experienced the highest decline among competitors ...